Literature DB >> 6855996

Familial nephropathy with hyperuricemia and gout.

E P Leumann, W Wegmann.   

Abstract

Chronic interstitial nephropathy with disproportionate hyperuricemia (serum uric acid 10.5-14.8 mg/dl [625-880 mumol/l] at a GFR of 40 ml/min/1.73 m2) was observed in 2 girls and their mother who suffered from gout since the age of 20 years. Urinary excretion of uric acid was normal. Renal biopsies in the 3 patients showed focal tubulointerstitial nephropathy. Absolute values of GFR remained stable in the 2 pediatric patients over a period of 10 years, whereas the older patient required dialysis at the age of 34 years. We speculate that this family suffers from a primary interstitial nephropathy which is accompanied by a subtle defect in tubular excretion of urate. A few similar observations have been reported in literature which suggests that dominantly inherited interstitial nephropathy with hyperuricemia and gout represents a distinct entity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6855996     DOI: 10.1159/000182979

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter.

Authors:  M S Lipkowitz; E Leal-Pinto; J Z Rappoport; V Najfeld; R G Abramson
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Autosomal dominant transmission of gouty arthritis with renal disease in a large Japanese family.

Authors:  N Yokota; H Yamanaka; Y Yamamoto; S Fujimoto; T Eto; K Tanaka
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

Review 3.  Gout, uric acid and purine metabolism in paediatric nephrology.

Authors:  J S Cameron; F Moro; H A Simmonds
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 4.  New developments in the epidemiology and genetics of gout.

Authors:  Raihana Zaka; Charlene J Williams
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.